| Revenue growth | 13% YoY in FY26; 15% growth guided for FY27. |
|---|---|
| Margins | EBITDA margins improved to 20%; targeting 22% and above. |
| Order book | Significant portion of planned capacity already committed. |
| Demand visibility | Strong; capacity for ibuprofen already 80% utilized. |
| Management confidence | High; citing benefits from backward integration and new capacity. |
Growth
FY26 Revenue increased 13% to ₹887cr; EBITDA grew 23% to ₹171cr with 20% margins.
Outlook
Guiding 15% revenue growth for FY27 with 22% EBITDA margin targets; ₹280cr brownfield capex ongoing.
Risks
Geopolitical tensions in Middle East impacting logistics, freight costs, and solvent prices.
Earnings Call filed with NSE, NSE: SMSPHARMA. Summary written with AI assistance from the document.
SMS Pharmaceuticals Ltd: key numbers
- Share price
- ₹468.85
- Market cap
- ₹4,156 Cr
- Revenue (annual)
- ₹886.9 Cr
- Net profit (annual)
- ₹102.0 Cr
- P/E (TTM)
- 40.6×Sector 47.3×
- Promoter holding
- 68.07%+0.00% QoQ
- FII holding
- 0.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from SMS Pharmaceuticals Ltd
All →SMS Pharmaceuticals Other Announcement
SMS Pharmaceuticals disclosed two market sell trades by Designated Person NVV Satyanarayana totalling ₹0.14 Crore. The PIT Reg 7(2) intimation involves a non-promoter designated person.
- Value
- ₹0.14 Cr
SMS Pharmaceuticals Annual General Meeting
SMS Pharmaceuticals Limited has scheduled its 38th Annual General Meeting for September 29, 2026. Key agenda items include dividend declaration, management re-appointments, and approval of material related party transactions.
SMS Pharmaceuticals Annual Report
SMS Pharmaceuticals Limited has released its Annual Report and Notice for the 38th Annual General Meeting scheduled for September 29, 2026. The company reported FY26 revenue of ₹887 Crore.
SMS Pharmaceuticals Credit Rating
CARE Ratings Limited has reaffirmed or revised the credit ratings for SMS Pharmaceuticals Limited's bank facilities. The review covers the company's long-term and short-term credit facilities.
SMS Pharmaceuticals Annual General Meeting
SMS Pharmaceuticals Limited has rescheduled its 38th Annual General Meeting to September 29, 2026. Consequently, the record date for the FY 2025-26 dividend is revised to September 22, 2026.
SMS Pharmaceuticals Capital Structure Change
N. Srilakshmi Padmini, an employee's immediate relative, purchased 3,000 equity shares of SMS Pharmaceuticals for ₹0.11 Crore via market purchase.
- Value
- ₹0.11 Cr